EGFR and hepatocellular carcinoma: A recent milestone study by Jin et al. reports the use of synthetic lethal CRISPR screen in discovering the synergistic effects of EGFR inhibitor and lenvatinib combination in HCC, achieving an approximately 50% of clinical responses in patients with advanced HCC who were unresponsive to lenvatinib1.